|Videos|August 24, 2022
Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence
Author(s)Rafael Fonseca, MD, Luciano Costa, MD, PhD
A key opinion leader explains whether doublet regimens still have a place in transplant-ineligible multiple myeloma treatment.
Advertisement
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5